Compare Snap Inc (SNAP) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Tempus AI — how do they compare? Snap Inc trades at $5.88 (market cap $9.83B), while Tempus AI trades at $70.55 (market cap $12.77B). The key difference: Tempus AI is the larger of the two by market cap, and Tempus AI is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snap Inc for 68 Days and Tempus AI for 22 Days on average.
| SNAP | TEM | |
|---|---|---|
Market Cap | $9.83B | $12.77B |
Volume | 28,532,342 | 8,980,490 |
Sector | Media | Broad Market / Factor |
52-Week High | $9.09 | $99.28 |
52-Week Low | $3.93 | $41.55 |
Typical Hold Time | 68 Days | 22 Days |
Enterprise Value | $11.39B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.81, up 0.17% with a bullish technical signal. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M vs -$1.4B in 2022). Recent news highlights AI integration in SPECS glasses with NVIDIA and Salesforce partnerships. Analyst consensus is mixed with 38% buy ratings and $7.78 price target, representing 34% upside potential.
Snap presents a turnaround story with improving financials but remains unprofitable. The stock offers potential upside from AI initiatives and revenue growth, balanced by competitive pressures and regulatory risks. Current valuation at 1.55 P/S appears reasonable for the growth trajectory, though profitability remains the key hurdle for sustained gains.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
